- Home
- IPHA vs CHPT Comparison
IPHA vs CHPT Comparison
Compare IPHA & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | CHPT |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 155.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | IPHA | CHPT |
|---|---|---|
| Price | $1.74 | $6.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 12 |
| Target Price | $5.00 | ★ $12.68 |
| AVG Volume (30 Days) | 16.7K | ★ 431.2K |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $417,083,000.00 |
| Revenue This Year | $28.31 | N/A |
| Revenue Next Year | N/A | $7.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.51 |
| 52 Week High | $2.63 | $12.62 |
Technical Indicators
Market Signals| Indicator | IPHA | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 48.19 |
| Support Level | $1.73 | $5.60 |
| Resistance Level | $1.90 | $6.76 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 75.18 | 53.26 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.